



+

TRANSMITTAL FORM <i>(to be used for all correspondence during pendency of filed application)</i>	Application Number	10/006,191	
	Filing Date	December 10, 2001	
	First Named Inventor	William Gaarde	
	Group Art Unit Number	1635	
	Examiner Name	McGarry, Sean	
Total Number of Pages in This Submission	7	Attorney Docket Number	23546-07665 (RTS-0274)

ENCLOSURES (check all that apply)	
<input type="checkbox"/> Fee Transmittal Form (in duplicate)	<input checked="" type="checkbox"/> Issue Fee Transmittal (in-duplicate)
<input checked="" type="checkbox"/> Return Receipt Postcard	<input checked="" type="checkbox"/> Check Enclosed
<input type="checkbox"/> Response to Notice to File Missing Parts	<input type="checkbox"/> Formal Drawing(s): [] Sheet(s) of Figure(s) []
<input type="checkbox"/> Assignment & Recordation Cover Sheet	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Declaration	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> Power of Attorney	<input type="checkbox"/> Certified Copy of Priority Document(s)
<input type="checkbox"/> Application Data Sheet	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Information Disclosure Statement & PTO/SB/08A <input type="checkbox"/> Copies of IDS Cited References	<input checked="" type="checkbox"/> Communication to Examiner (4 pp)
<input type="checkbox"/> Request for Corrected Filing Receipt	<input type="checkbox"/>
<input type="checkbox"/> Request for Correction of Recorded Assignment	<input type="checkbox"/>
<input type="checkbox"/> Amendment/Response: [] Page(s) <input type="checkbox"/> After Final	<input type="checkbox"/>
<input type="checkbox"/> Status Request	<input type="checkbox"/>
<input type="checkbox"/> Revocation and Substitute Power of Attorney	<input type="checkbox"/>
REMARKS:	

SIGNATURE OF ATTORNEY OR AGENT			
Signature:			
Attorney/Reg. No.:	Susan T. Hubl, Ph.D., Patent Agent, Reg. No. 47,668	Dated:	June 10, 2005

CERTIFICATE OF MAILING			
I hereby certify that this correspondence, including the enclosures identified above, is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below. If the Express Mail Mailing Number is filled in below, then this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service pursuant to 37 CFR 1.10.			
Signature:			
Typed or Printed Name:	Susan T. Hubl	Dated:	June 10, 2005
Express Mail Mailing Number (optional):			



IN THE UNITED STATES
PATENT AND TRADEMARK OFFICE

APPLICANT(S):	GAARDE ET AL
APPLN NO.:	10/006,191
FILING DATE:	12/10/2001
TITLE:	ANTISENSE MODULATION OF CONNECTIVE TISSUE GROWTH FACTOR EXPRESSION
EXAMINER:	MCGARRY
GAU:	1635
ATTY. DKT. NO.:	23546-07665/US (RTS-274)
CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below. Dated: <u>6/10/05</u> By: <u>Susan T. Hubl</u> Susan T. Hubl, Reg. No.: 47,668	

COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

COMMUNICATION TO THE EXAMINER

SIR:

Responsive to the Notice of Allowability and Examiner's Amendment dated March 11, 2005 received in the above-identified patent application, Applicant respectfully points out that the Examiner's stated that he was amending Claim 2, a canceled claim. As discussed in the telephone call of March 2, 2005, the Examiner's Amendment should be to Claim 3. For the convenience of the Examiner, Applicant is providing a copy of the allowed claims, including the correct Examiner's Amendment to Claim 3. No amendments are currently presented.

Amendments to the Claims begin on page 2. **Remarks** begin on page 4.

ALLOWED CLAIMS (NO CURRENT AMENDMENTS)

1. **(Previously amended)** A compound 8 to 50 nucleobases in length targeted to nucleobases 2212 through 2238 of a nucleic acid molecule encoding connective tissue growth factor (SEQ ID NO:19), wherein said compound specifically hybridizes with said nucleic acid molecule encoding connective tissue growth factor and inhibits the expression of connective tissue growth factor, wherein said compound is an antisense oligonucleotide and wherein said antisense oligonucleotide comprises at least one modification selected from the group consisting of a modified internucleoside linkage, a modified sugar moiety, and a modified nucleobase.

2. **(Canceled)**

3. **(Previously amended)** An antisense oligonucleotide up to 50 nucleobases in length targeted to nucleobases 2212 through 2238 of a nucleic acid molecule encoding connective tissue growth factor (SEQ ID NO:19), wherein said antisense oligonucleotide specifically hybridizes with said nucleic acid molecule encoding connective tissue growth factor and inhibits the expression of connective tissue growth factor and wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO: 47, 48, 63, or 64.

4. **(Previously amended)** The compound of claim 1 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

5. **(Original)** The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.

6. **(Previously amended)** The compound of claim 1 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

7. **(Original)** The compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

8. **(Previously amended)** The compound of claim 1 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

9. **(Original)** The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.

10. **(Previously amended)** An antisense oligonucleotide 8 to 50 nucleobases in length targeted to nucleobases 2212 through 2238 of a nucleic acid molecule encoding connective tissue growth factor (SEQ ID NO:19), wherein said antisense oligonucleotide specifically hybridizes with said nucleic acid molecule encoding connective tissue growth factor and inhibits the expression of connective tissue growth factor and wherein the antisense oligonucleotide is a chimeric oligonucleotide.

11. **(Canceled)**

12. **(Original)** A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

13. **(Original)** The composition of claim 12 further comprising a colloidal dispersion system.


14-20. **(Canceled)**

CONCLUSION

As described above, the Examiner's Amendments should be directed to Claim 3, and not Claim 2; the allowed claims are as listed above. If the Examiner has any questions concerning this Communication, the Examiner is invited to telephone Applicant's representative at (415) 875-2316.

Respectfully submitted,
GAARDE ET AL

Dated: 6/10/05

By: 

Susan T. Hubl, Ph.D., Patent Agent

Reg. No.: 47,668

Fenwick & West LLP

Silicon Valley Center, 801 California Street

Mountain View, CA 94041

Tel: (415) 875-2316

Fax: (650) 938-5200